Shilpa Pharma, Inc. v. Novartis Pharmaceuticals Corporation
1:21-cv-00558
Overview
Parties
Notice Only
Special Master
Sue L. Robinson NPE (Individual / Inventor)
Represented By
0 Attorneys ListedCounter Claimant
Novartis Pharmaceuticals Corporation Operating Company
Represented By
11 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Counter Defendant
Akshay Kant Chaturvedi NPE (Individual / Inventor)
Represented By
0 Attorneys ListedPrashant Purohit NPE (Individual / Inventor)
Represented By
0 Attorneys ListedVinod Kumar Singh NPE (Individual / Inventor)
Represented By
0 Attorneys ListedVimal Kumar Shrawat NPE (Individual / Inventor)
Represented By
0 Attorneys ListedShilpa Medicare Limited NPE (University / Research)
Represented By
1 Attorneys ListedSmith, Katzenstein, & Jenkins LLP
1000 West Street, Suite 1501, Wilmington, DE 19801
Shilpa Pharma, Inc. Operating Company
Represented By
9 Attorneys ListedSmith, Katzenstein & Jenkins LLP
1000 N. West Street, PO Box 410
Smith, Katzenstein, & Jenkins LLP
1000 West Street, Suite 1501, Wilmington, DE 19801
Smith, Katzenstein, & Jenkins LLP
1000 West Street, Suite 1501, Wilmington, DE 19801
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 2 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | Asserted | Asserted Patent | View Official Patent → |
| 🌐 PCT International (WIPO) | PCT World Application | View Official Patent → |
Novartis Pharmaceuticals Corporation v. Shilpa Pharma, Inc.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US9266816
Fingolimod polymorphs and their processes
|
Filed: 2011-08-29
Issued: 2016-02-23
|
Active (4.8 yrs remaining)
Expires: 2031-08-29
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term — No obviousness-type double patenting noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
72
Dispositive
12
Granted
3
Denied
2
Pending / Review
49
Motions by Category
Key Dispositive Motions & Rulings